Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Luye Pharma Group ( (HK:2186) ) has provided an announcement.
Luye Pharma Group has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing, a subsidiary of CNS-focused specialist Jiangsu Nhwa Pharmaceutical, exclusive rights to commercialize three long-acting injectable antipsychotics—Rykindo, Ruibailai and Meibirui—in mainland China, all indicated for schizophrenia. Under the 10-year agreement, Luye retains product ownership, regulatory approvals, intellectual property and manufacturing responsibilities, while Nhwa will handle distribution and commercialization through its nationwide network of more than 10,000 hospitals and extensive presence in mental health and primary care institutions, in return for a one-off US$20 million licensing fee. The partnership aligns two leading CNS players to expand access to differentiated long-acting schizophrenia treatments, particularly at the community and primary-care level, supporting better adherence and relapse prevention in a market of around 8 million patients, and is expected to accelerate value creation from Luye’s CNS pipeline and reinforce both companies’ positioning in China’s rapidly developing CNS therapeutics segment.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group is a Bermuda-incorporated, Hong Kong-listed pharmaceutical company with a strategic focus on central nervous system (CNS) therapies. Leveraging its Long-Acting and Extended-Release Platform, the group has developed a competitive CNS portfolio in China, including innovative long-acting injectable antipsychotics targeting schizophrenia and other psychiatric and neurological disorders, and is prioritizing both innovation and global expansion.
Average Trading Volume: 24,226,770
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.24B
For a thorough assessment of 2186 stock, go to TipRanks’ Stock Analysis page.